|
May 6
|
BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024
|
|
Apr 17
|
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting
|
|
Apr 10
|
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement
|
|
Apr 1
|
BioLineRx Announces $6 Million Registered Direct Offering
|
|
Mar 27
|
BioLineRx Ltd. (NASDAQ:BLRX) Q4 2023 Earnings Call Transcript
|
|
Mar 27
|
BLRX: First Aphexda Sales Recognized
|
|
Mar 26
|
BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates
|
|
Mar 20
|
BioLineRx to Report 2023 Annual Financial Results on March 26, 2024
|
|
Mar 4
|
BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production
|
|
Feb 16
|
BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT® and CIBMTR®
|
|
Dec 21
|
BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease
|
|
Nov 20
|
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates
|
|
Nov 2
|
3 Tech Stocks That Wall Street Loves More Than Nvidia
|
|
Sep 11
|
BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma
|
|
Sep 5
|
BLRX: On Your Marks, Get Set…
|
|
May 24
|
BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates
|